Durvalumab + Olaparib Yields Durable Responses in DDR-Mutated Metastatic Pancreatic Cancer in Phase 2 Trial

Default Digital Object Group 2026 Dataset

View at publisher
DOI: 10.1200/adn.25.300416
Cited by: 0

Abstract

The combination of durvalumab and olaparib offers promising antitumor activity in patients with metastatic pancreatic cancer and DNA damage repair gene alterations who had previously undergone platinum-based chemotherapy, according to results of a phase 2 study (Abstract 724).

Publication details

Journal / source
Default Digital Object Group
Publication date
5 January 2026
Document type
Dataset